Home・Lista de Ações・Moderna Inc

Moderna Inc

Fechado

SetorSaúde

63.15 -0.71

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

60.62

Máximo

63.76

Indicadores-chave
By Trading Economics
Rendimento	561M -782M
Vendas	-244M 145M
EPS	-1.97
Margem de lucro	-539.31
Funcionários	4,700
EBITDA	554M -704M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-22.74% downside

Dividendos
By Acuity
Próximos Ganhos	5 de nov. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1.8B 24B
Abertura anterior	63.86
Fecho anterior	63.15

Sentimento de Notícias

By Acuity

50%

163 / 340 Ranking em Healthcare

Moderna Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de ago. de 2026, 23:51 UTC

Social Media

Moderna shares are lower in after-market hours amid concerns over the FDA's approval of its mRNA flu vaccine and modest trial data effectiveness.

13 de ago. de 2026, 23:21 UTC

Social Media

Moderna's first mRNA flu shot receives FDA approval, despite concerns over a high adverse reaction rate. Shares are higher in after-market trading.

12 de ago. de 2026, 23:51 UTC

Moderna Inc shares are lower in after-market hours with no specific news identified. Recent easing inflation has influenced broader market sentiment.

10 de ago. de 2026, 19:36 UTC

Social Media

The FDA has approved Moderna's mRNA flu vaccine for adults 50 and older. Shares are advancing modestly amid concerns over safety and efficacy.

7 de ago. de 2026, 19:52 UTC

Social Media

The FDA approved Moderna's mRNA flu vaccine, mFlusiva, for adults 50 and older. Shares are higher during Friday's trading session.

6 de ago. de 2026, 23:06 UTC

Social Media

Moderna's mRNA flu vaccine, "mFlusiva," receives FDA approval for adults aged 50 to 64, boosting shares higher in after-market trading.

5 de ago. de 2026, 19:46 UTC

Social Media

Event

Moderna Inc. shares are lower as disappointing ADP employment data weighs on market sentiment. The FDA has set a decision date for its mFlusiva vaccine.

4 de ago. de 2026, 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3 de ago. de 2026, 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31 de jul. de 2026, 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30 de jul. de 2026, 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29 de jul. de 2026, 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28 de jul. de 2026, 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27 de jul. de 2026, 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24 de jul. de 2026, 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23 de jul. de 2026, 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21 de jul. de 2026, 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20 de jul. de 2026, 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Comparação entre Pares

Variação de preço

Moderna Inc Previsão

Preço-alvo

By TipRanks

-22.74% parte inferior

Previsão para 12 meses

Média 48.92 USD -22.74%

Máximo 77 USD

Mínimo 39 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Moderna Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

15 ratings

Comprar

Manter

Vender

Com base em 15 analistas que deram avaliações de ações para Moderna Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

163 / 340 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.